Wendy's cut to sell from buy by Argus Research
WEN•Argus Research cut its rating on Wendy's to sell from buy.
Related News
FDA clears Eloxx's Exaluren for Phase 2 trial in ADPKD
ELOX•
Medical Properties Trust Q3 revenue rises
MPW•
Nuvation Bio expands Phase 3 safusidenib glioma trial to six European countries
NUVB•
Incyte raises 2026 net sales forecast to $5.21 billion-$5.3 billion
INCY•
NeuroOne's OneRF delivers immediate pain relief in 14 of 15 patients in initial study
NMTC•